Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Phase 3
- Conditions
- Hepatocellular CarcinomaLiver Transplantation
- Interventions
- Drug: relenvatinib
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04237740
Prospective, Observational Real-world Treatments of AEDH in Large-scale Surgical Cases
Recruiting
- Conditions
- Epidural HematomaDecompressive CraniectomyCraniotomy
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04229966
- Locations
- 🇨🇳
Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer
Not Applicable
Not yet recruiting
- Conditions
- Prostate CancerHormone Sensitive Prostate CancerChemotherapy EffectLocally Advanced Prostate Carcinoma
- Interventions
- Drug: Neoadjuvant hormone therapyDrug: Neoadjuvant chemotherapy combined with hormone therapyProcedure: Radical Prostatectomy (RP)+ extended lymph node dissection
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 475
- Registration Number
- NCT04220398
Early Prediction of QFR in STEMI-Pharmaco-invasice
- Conditions
- ST Segment Elevation Myocardial Infarction
- Interventions
- Diagnostic Test: Computation of quantitative flow ratio
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04220736
- Locations
- 🇨🇳
Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
Phase 2
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04202484
Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD
Phase 4
- Conditions
- Myocardial InjuryConnective Tissue Diseases
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04197050
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Effects of Artificial Sweeteners on Glucose Metabolism in Patients With Type 2 Diabetes
Not Applicable
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dietary Supplement: sucralose
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04185662
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT04183478
- Locations
- 🇨🇳
RenJiH, Shanghai, Shanghai, China
KN035 in Patients With Advanced Multiple Primary Tumors
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04182789
- Locations
- 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China
SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Not Applicable
Completed
- Conditions
- Pancreatic Cancer Stage IV
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04181645
- Locations
- 🇨🇳
RenJiH, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath